Ergoloid Mesylates
( Dihydrogenated Ergot Alkaloids ; Dihydroergotoxine ) Pronunciation: (err-GO-loyd MEH-suh-lates)Class: Psychotherapeutic agent
Trade Names:
Gerimal
- Tablets, oral 1 mg
- Tablets, sublingual 0.5 mg
- Tablets, sublingual 1 mg
Trade Names:
Hydergine
- Liquid 1 mg/mL
- Tablets, oral 1 mg
- Tablets, sublingual 0.5 mg
- Tablets, sublingual 1 mg
Pharmacology
 | ||||||||||||
 User Reviews & Ratings
Compare with other drugs.
| ||||||||||||
Unknown; may increase brain metabolism, possibly increasing cerebral blood flow.
Pharmacokinetics
Absorption
Approximately 25% is absorbed; approximately 50% is removed by the first-pass metabolism. T max is 1.5 to 3 h.
Distribution
Excreted in breast milk.
Metabolism
Undergoes first-pass metabolism.
Elimination
The t ½ is approximately 2.6 to 5.1 h (unchanged ergoloid in the plasma).
Indications and Usage
Treatment of age-related decline in mental capacity, primary progressive dementia, Alzheimer dementia, multi-infarct dementia and senile onset.
Contraindications
Hypersensitivity to ergoloid mesylates or other ergot alkaloids; acute or chronic psychosis.
Dosage and Administration
AdultsPO/SL 1 to 2 mg 3 times daily (up to 12 mg/day has been used).
General Advice
Instruct patient to allow SL tablets to completely dissolve under tongue; do not allow patient to swallow, crush, or chew tablet.
Storage/Stability
Store in tightly closed, light-resistant container at room temperature.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Cardiovascular
Orthostatic hypotension; bradycardia.
Dermatologic
Rash.
GI
Transient nausea; GI disturbances; sublingual irritation.
Precautions
Pregnancy
Pregnancy category undetermined.
Lactation
Undetermined.
Children
Safety and efficacy not established.
Hepatic Function
Elimination of drug may be affected.
Special Risk Patients
Administer drug with caution to patients with history of bradycardia or hypotension.
Overdosage
Symptoms
Headache, flushing, anorexia, nausea, vomiting, abdominal cramps, nasal congestion, impaired vision, dizziness, fainting.
Patient Information
- Teach patient how to decrease effects of orthostatic hypotension by rising slowly from supine position and dangling feet for few min before standing.
- Instruct patient to avoid alcohol consumption, which may enhance hypotensive effect.
- Caution patient not to take OTC cough, cold and allergy preparations that contain alcohol.
- Instruct patient to avoid excessive exposure to cold since temperature regulation may be impaired.
- Instruct patient to notify health care provider if adverse reactions occur.
- Advise patient/family that it may require 3 to 4 wk and up to 6 mo to determine clinical effectiveness of drug.
 |
Link to Page |  |
Print Page |  |
Email Page |  | Add to List |
Ergoloid Mesylates (Dihydrogenated Ergot Alkaloids; Dihydroergotoxine) Side Effects
Compare Ergoloid Mesylates (Dihydrogenated Ergot Alkaloids; Dihydroergotoxine) with other medications for the treatment of:
Dementia, Alzheimer's Disease, Arteriosclerotic Dementia
User reviews
0 review(s) for Ergoloid Mesylates (Dihydrogenated Ergot Alkaloids; Dihydroergotoxine)
